NasdaqGS - Delayed Quote • USD
Cullinan Therapeutics, Inc. (CGEM)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:50 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
18,943.00
--
Operating Expense
190,649.00
190,649.00
132,137.00
86,897.00
60,335.00
Operating Income
-190,649.00
-190,649.00
-132,137.00
-67,954.00
-60,335.00
Net Non Operating Interest Income Expense
21,627.00
21,627.00
6,611.00
477.00
888.00
Other Income Expense
-201.00
-201.00
276,842.00
-8.00
-11.00
Pretax Income
-169,223.00
-169,223.00
151,316.00
-67,485.00
-59,458.00
Tax Provision
-14,122.00
-14,122.00
42,121.00
--
--
Net Income Common Stockholders
-153,162.00
-153,162.00
111,214.00
-65,570.00
-51,799.00
Diluted NI Available to Com Stockholders
-153,162.00
-153,162.00
111,214.00
-65,570.00
-51,799.00
Basic EPS
-3.69
--
2.46
-1.52
-1.37
Diluted EPS
-3.69
--
2.38
-1.52
-1.37
Basic Average Shares
41,550.00
--
45,164.00
43,077.00
41,397.85
Diluted Average Shares
41,550.00
--
46,640.00
43,077.00
41,397.85
Total Operating Income as Reported
-191,089.00
-191,089.00
144,648.00
-67,954.00
-60,335.00
Rent Expense Supplemental
--
--
--
--
914.00
Total Expenses
190,649.00
190,649.00
132,137.00
86,897.00
60,335.00
Net Income from Continuing & Discontinued Operation
-153,162.00
-153,162.00
111,214.00
-65,570.00
-51,799.00
Normalized Income
-152,758.74
-152,758.74
-88,597.09
-65,570.00
-51,799.00
Interest Income
21,627.00
21,627.00
6,611.00
477.00
888.00
Net Interest Income
21,627.00
21,627.00
6,611.00
477.00
888.00
EBIT
-190,649.00
-190,649.00
-132,137.00
-67,954.00
-60,335.00
EBITDA
-190,339.00
-190,339.00
-132,044.00
-67,901.00
-60,273.00
Reconciled Depreciation
310.00
310.00
93.00
53.00
62.00
Net Income from Continuing Operation Net Minority Interest
-153,162.00
-153,162.00
111,214.00
-65,570.00
-51,799.00
Total Unusual Items Excluding Goodwill
-440.00
-440.00
276,785.00
--
--
Total Unusual Items
-440.00
-440.00
276,785.00
--
--
Normalized EBITDA
-189,899.00
-189,899.00
-408,829.00
-67,901.00
-60,273.00
Tax Rate for Calcs
0.00
0.00
0.00
--
--
Tax Effect of Unusual Items
-36.74
-36.74
76,973.91
--
--
12/31/2020 - 1/8/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IGMS IGM Biosciences, Inc.
9.40
+22.88%
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
MRUS Merus N.V.
45.04
+0.24%
ELYM Eliem Therapeutics, Inc.
3.9800
+17.40%
ACRV Acrivon Therapeutics, Inc.
8.46
-0.12%
MLTX MoonLake Immunotherapeutics
42.49
+0.57%
ALXO ALX Oncology Holdings Inc.
16.86
-0.06%
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
KYTX Kyverna Therapeutics, Inc.
15.47
-2.95%
ZNTL Zentalis Pharmaceuticals, Inc.
11.06
+0.68%